Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
59 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Chemotherapy Induced Anemia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H1 2017, provides an overview of the Chemotherapy Induced Anemia (Toxicology) pipeline landscape. Chemotherapy-induced anemia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness, cognitive impairment, loss of sexual desire, inability to perform daily functions and/or depression associated with anemia. The predisposing factors include age, co-morbidities, time course of therapy. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Anemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Chemotherapy Induced Anemia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 2, 3 and 6 respectively. Chemotherapy Induced Anemia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia (Toxicology). - The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Chemotherapy Induced Anemia (Toxicology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Chemotherapy Induced Anemia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia (Toxicology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Anemia (Toxicology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia (Toxicology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Chemotherapy Induced Anemia - Overview Chemotherapy Induced Anemia - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Chemotherapy Induced Anemia - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 3SBio Inc Chong Kun Dang Pharmaceutical Corp Dr. Reddy's Laboratories Ltd Galenica Ltd Novartis AG Panacea Biotec Ltd Pfizer Inc PharmaEssentia Corp PhytoHealth Corp Pieris Pharmaceuticals Inc SBI Pharmaceuticals Co Ltd Therapure Biopharma Inc Tolero Pharmaceuticals Inc Chemotherapy Induced Anemia - Drug Profiles (aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress darbepoetin alfa biosimilar - Drug Profile Product Description Mechanism Of Action R&D Progress epoetin alfa - Drug Profile Product Description Mechanism Of Action R&D Progress epoetin zeta - Drug Profile Product Description Mechanism Of Action R&D Progress ferric carboxymaltose - Drug Profile Product Description Mechanism Of Action R&D Progress pegylated erythropoietin - Drug Profile Product Description Mechanism Of Action R&D Progress PHEP-01 - Drug Profile Product Description Mechanism Of Action R&D Progress PRS-080 - Drug Profile Product Description Mechanism Of Action R&D Progress SSS-06 - Drug Profile Product Description Mechanism Of Action R&D Progress TBI-304H - Drug Profile Product Description Mechanism Of Action R&D Progress TP-0184 - Drug Profile Product Description Mechanism Of Action R&D Progress TP-0413 - Drug Profile Product Description Mechanism Of Action R&D Progress TXA-302 - Drug Profile Product Description Mechanism Of Action R&D Progress Chemotherapy Induced Anemia - Dormant Projects Chemotherapy Induced Anemia - Discontinued Products Chemotherapy Induced Anemia - Product Development Milestones Featured News & Press Releases Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology Oct 21, 2011: ALA Study Results Presented at 39th Annual Meeting of Japanese Association for Acute Medicine Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting Oct 03, 2011: ALA Study Results Presented at Japanese Society of Parasitology, 71st Meeting Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended Aug 09, 2010: Dr Reddy's Launches Darbepoetin Alfa For Treatment Of Anemia In India Feb 22, 2010: Retacrit Received a Positive Opinion From the European Committee for Medicinal Products for Human Use (CHMP) for Subcutaneous (SC) use in Renal Anaemia Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar Jan 07, 2008: Sandoz and Gambro form strategic alliance Dec 19, 2007: Hospira's Retacrit Receives Marketing Authorization in the EU Oct 18, 2007: Hospira's Biosimilar Epoetin Retacrit Receives Positive Opinion Recommending EU Approval Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Chemotherapy Induced Anemia, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Chemotherapy Induced Anemia - Pipeline by 3SBio Inc, H1 2017 Chemotherapy Induced Anemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2017 Chemotherapy Induced Anemia - Pipeline by Galenica Ltd, H1 2017 Chemotherapy Induced Anemia - Pipeline by Novartis AG, H1 2017 Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Ltd, H1 2017 Chemotherapy Induced Anemia - Pipeline by Pfizer Inc, H1 2017 Chemotherapy Induced Anemia - Pipeline by PharmaEssentia Corp, H1 2017 Chemotherapy Induced Anemia - Pipeline by PhytoHealth Corp, H1 2017 Chemotherapy Induced Anemia - Pipeline by Pieris Pharmaceuticals Inc, H1 2017 Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co Ltd, H1 2017 Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc, H1 2017 Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals Inc, H1 2017 Chemotherapy Induced Anemia - Dormant Projects, H1 2017 Chemotherapy Induced Anemia - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
